OSIVAX - OSIVAX - CLINICAL PROOF OF CONCEPT OF OVX836, A SINGLE-SHOT BROADLY PROTECTIVE INFLUENZA A VACCINE FOR IMMEDIATE PROTECTION AGAINST EMERGING PANDEMIC STRAINS
Key Details
Description
OSIVAX - CLINICAL PROOF OF CONCEPT OF OVX836, A SINGLE-SHOT BROADLY PROTECTIVE INFLUENZA A VACCINE FOR IMMEDIATE PROTECTION AGAINST EMERGING PANDEMIC STRAINS
Context & Analysis
On Nov 13, 2025, Department of Health and Human Services obligated $19,485,392 to OSIVAX for osivax - clinical proof of concept of ovx836, a single-shot broadly protective influenza a vaccine for immediate protection against emerging pandemic strains. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost sharing contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. The contract is scheduled through Jul 24, 2028. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Market context
- Recompete outlook
- Ends Jul 24, 2028, in 21 months. Recompete signal as of Oct 20, 2026: 26/100, combining time to the end date, the incumbent's history with this agency, whether the award was competed, and its size.
- Competition
- Competed, with 1 offer. 96% of 222 awards in this market (Department of Health and Human Services awards in NAICS 541714 over the last 3 years) were competed; median 1 offers.
- Award size
- At $19.5M, this award is larger than three in four of the 212 priced Department of Health and Human Services awards in NAICS 541714 over the last 3 years (median $1.2M).
- Incumbent at this agency
- OSIVAX has 1 other award from Department of Health and Human Services, totalling $744K, in 2026.
- Largest vendors in this market
By obligations, Department of Health and Human Services awards in NAICS 541714 over the last 3 years.
- TECHNICAL RESOURCES INTERNATIONAL, INC. — 4 awards, $379.6M
- ALLUCENT GOVERNMENT SERVICES (US) LLC — 2 awards, $373.2M
- ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC. — 4 awards, $342.2M
- PARATEK PHARMACEUTICALS, INC — 1 award, $265.3M
- GENENTECH INC — 1 award, $243.7M
Computed from USAspending award data on Oct 20, 2026.
Contractor Information
Related Opportunities
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.